Nonsurgical Rhinoplasty: a Safety of Calcium Hydroxyapatite Filler Used for Nose Sculpt - Luminera

Nonsurgical Rhinoplasty: a Safety of Calcium Hydroxyapatite Filler Used for Nose Sculpt

Share on facebook
Share on linkedin
Share on whatsapp
Share on email
David Mor-Yosef, MD; Konstantin Konfino, MD, PhD; Roni Moscona, MD

The use of dermal fillers for a nonsurgical rhinoplasty requires a medical knowledge of nasal anatomy. The deep fatty layer is targeted as it is known as the safe plan for filler deposition. Therefore, the filler should be injected exactly underneath the fibromuscular layer and above the perichondrium/periosteum layer in order to avoid a superficial injection or an inaccurate injection into the nose’s major blood vessels and artery systems [1– –5]. The advantages of a calcium hydroxyapatite filler used for nose sculpt arise from its ability to alter the shape of the nose at the anatomic region where it was positioned [6–8]. Also, when injected directly, the filler has the ability to correct aesthetic deformities without having the patient go through a complicated rhinoplasty procedure [9,10]. Moreover, it can also be used for the correction of postrhinoplasty deformities [11].

The primary aim of the study detailed in the included article was to assess the safety of Crystalys, a calcium hydroxyapatite injectable filler, used in nonsurgical rhinoplasty as well as its performance within a six-month period. The results of the study demonstrated that Crystalys is safe for nonsurgical rhinoplasty and holds a constant high level of performance.

The dermal filler of choice used in this study was Crystalys, a calcium hydroxyapatite injectable filler (Panaxia Ltd.). Crystalys is a sterilized, apyrogenic, long lasting and non-permanent injectable facial implant. It is a homogenous, semi-solid implant, intended for sub- and deep-dermal use, it is provided in a 1.25 mL pre-filled graduated, glass syringe. The filler is based on synthetic calcium hydroxyapatite, the major material of teeth and bones [12]. It consists of microspheres of calcium hydroxyapatite formulated to a concentration of 55.7% CaHA, suspended in an aqueous gel carrier of glycerol and sodium carboxymethylcellulose. When injected, the CaHA microspheres form a framework for ingrowth by fibroblasts, which steadily substitute the carrier vehicle.

full article
Please Sign Up to Continue